Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atabecestat - Janssen Pharmaceuticals

Next Previous
Drug Profile

Atabecestat - Janssen Pharmaceuticals

Alternative Names: JNJ-54861911; RSC-385896

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Janssen Research & Development
  • Class Amides; Antidementias; Small molecules; Thiazines
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 Jul 2019 Final efficacy and adverse events data from a phase II/III EARLY trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2019 (AAIC-2019)
  • 28 Jun 2018 Janssen Research & Development completes a phase II trial in Alzheimer's disease (In adults, In the elderly) in Belgium, France, Germany, Netherlands, Spain and Sweden (PO) (NCT02406027)
  • 04 Jun 2018 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top